^
Association details:
| Biomarker: | CD20 expression |
|---|---|
| Cancer: | Lymphoma |
| Drug: | avipendekin pegol (NKTR-255) (IL-15R agonist) + Ritucad (rituximab biosimilar) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and mechanism of action of NKTR-255, a polymer-conjugated IL-15 receptor agonist in hematological tumors.
Published date:
05/26/2019
Excerpt:
NKTR-255 demonstrated synergistic activity and provided a long-term survival benefit when combined with daratumumab or rituximab in the CD38 and CD20-expressing lymphoma mouse models...
DOI:
10.1200/JCO.2019.37.15_suppl.e19512
